
Cat. #156528
Anti-CD134 ligand (OX40 ligand) [OX89]
Cat. #: 156528
Unit size: 100 ug
Availability: 10-12 weeks
Target: OX40 ligand
Class: Monoclonal
Application: FACS
Reactivity: Mouse
Host: Rat
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Medical Research Council; University of Oxford
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-CD134 ligand (OX40 ligand) [OX89]
- Alternate name: CD134 ligand
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Mouse
- Host: Rat
- Application: FACS
- Description: This antibody recognises the ligand for OX40 (CD134 ligand) on dendritic cells and some activated lymphocytes.
- Immunogen: Con A activated mouse spleen
- Myeloma used: NS1
- Recommended controls: IgG1
Target Details
- Target: OX40 ligand
- Target background: This antibody recognises the ligand for OX40 (CD134 ligand) on dendritic cells and some activated lymphocytes.
Applications
- Application: FACS
Handling
- Format: Liquid
- Unit size: 100 ug
- Shipping conditions: Dry ice
References
- Malmstr??m et al. 2001. J Immunol. 166(11):6972-81. PMID: 11359859.
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)

![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)


